INVESTOR RELATIONS

INVEST IN THE FUTURE OF HEALTHCARE

FUNDRAISING: PRESS RELEASE

INVEST IN THE FUTURE OF HEALTHCARE: CARDIO AI SEEKS INVESTORS FOR $10 MILLION SEED ROUND FUNDING. Cardio AI, a groundbreaking healthcare technology startup, is inviting visionary investors to participate in its $10 million seed round funding. This investment opportunity is set to revolutionize the landscape of cardiovascular healthcare by harnessing the power of precision medicine and cutting-edge Artificial Intelligence. The funds raised will be pivotal in developing and deploying the innovative AI diagnostic and treatment system powered by CARDIO AI MedConnect Platform technology for seamless electronic data collection and advanced processing, medication and treatment management, cardiovascular diagnostic and treatment system (DTS), real-time monitoring and feedback, remote monitoring and feedback. This infrastructure will play a crucial role in training and validating state-of-the-art AI algorithms. These algorithms are engineered to deliver precise diagnoses for critical cardiovascular conditions such as Myocardial Infarction (MI), Heart Failure (HF), Congenital Heart Disease, and Cardiac Arrhythmias. Cardio AI's vision extends beyond diagnostic precision alone. By utilizing AI capabilities, the company aims to offer personalized treatment recommendations to individual patients based on their genetic markers and medical data. Moreover, the algorithms will enhance the precision of prognosis, analyzing treatment responses, disease progression, and predicting time-to-event outcomes, especially post MI complications with unparalleled accuracy. "This is a unique opportunity to be at the forefront of the future of cardiovascular healthcare," emphasized Tamanna Nahar: MD, MBA, Executive President &Chief Medical Director at Cardio AI. "Investors joining us on this journey will not only be driving innovation but will also be contributing to improved patient outcomes and personalized treatment strategies that can reshape the industry." “This investment opportunity is not just about funding a company; it’s about shaping the future of healthcare. “Investor who join us on this journey will also help drive innovation in precision medicine, Scientific research and new drug discovery, ultimately leading to better patient outcomes and transformative advancements in cardiovascular healthcare,” highlighted Tamanna Nahar: MD, MBA, Executive President &Chief Medical Director at Cardio AI. Invest in Cardio AI today to be part of a transformative journey towards redefining cardiovascular healthcare through precision medicine, indicated Sampson Kontomah CEO and Chief Product Architect CARDIO AI. ABOUT CARDIO AI: Cardio AI is a pioneering healthcare technology company dedicated to revolutionizing cardiovascular healthcare through the integration of AI algorithms and precision medicine. By leveraging cutting-edge technology, Cardio AI aims to provide accurate diagnoses, personalized treatment recommendations, and precise prognostic insights for patients with cardiovascular conditions. "We’re at the forefront of transforming cardiovascular healthcare through the innovative integration of AI algorithms and precision medicine. Our mission is to revolutionize how cardiovascular conditions are diagnosed, treated, and managed by harnessing the power of advanced technology. CARDIO AI “MedConnect platform can analyze vast amounts of patient data with unprecedented speed and accuracy, enabling healthcare professionals (HCPs) to make more informed decisions”, articulated Sampson Kontomah: CEO & Chief Product Architect of CARDIO AI. In addition to diagnosis and treatment, Cardio AI is committed to providing precise prognostic insights that enable HCPs to anticipate and prevent potential complications before they arise by forecasting post MI complications, time to event analysis and survival rates. Leveraging advanced AI and ML techniques for predictive modeling and risk assessment we can precisely predict and diagnose MI with certainty, identify early warning signs and develop proactive strategies to optimize patient outcomes, improve quality of life and minimize risks. Through collaboration with leading healthcare institutions, researchers, and industry partners, we are pioneering a new era of healthcare where technology and innovation converge to deliver personalized, precise, and effective effective diagnosis and treatments." For investment inquiries, please contact: Email : [email protected], Tel : +16149678728 Website : www.cardioailive.com CONTACTS: Sampson Kontomah Founder: CEO & Chief Product Architect CARDIO AI Email: [email protected] Tel: +1614-967-8728 Tamanna Nahar: MD, MBA Executive President: Chief Medical Director CARDIO AI Email: [email protected] Tel: +12013147922